CytomX reports positive Phase 1a data for CX-904: no CRS, 33% response rate in pancreatic cancer

CytomX Therapeutics, Inc.

CX-904 demonstrated favorable safety: no CRS of any grade in step-dosing; no Grade >1 CRS overall.
In 6 efficacy-evaluable pancreatic cancer patients, 2 confirmed partial responses (33%) and all 6 had disease control.
One patient achieved 83% tumor reduction at 6 mg; another 51% at 5 mg; both remained on treatment.
Preliminary PK/PD data support PROBODY T-cell engager mechanism: maintained masking and CD8+ T-cell margination.
Dose escalation continues; Phase 1b expansion in EGFR-positive tumors planned with partner Amgen.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.